KOL Webinar on the Nature Medicine Case Report: Visual Recovery after GS030 Optogenetic Treatment

GenSight Biologics Announces Nature Medicine Case Report Showing Visual Recovery after GS030 Optogenetic Treatment

GenSight Biologics Appoints Country Leads for France, Germany and the UK in Preparations for LUMEVOQ® Commercial Launch

Advanced Therapies – Virtual

GenSight Biologics Appoints Françoise de Craecker to its Board of Directors

GenSight Biologics Provides 2021 Operations Update in the Context of COVID-19

GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye

Annual General Meeting 2021

GenSight Biologics Reports Cash Position as of March 31, 2021 and Provides Operational Update

GenSight Biologics Announces the Filing of its 2020 Universal Registration Document